Enanta Pharmaceuticals (ENTA) Operating Income Growth (3y) (2015 - 2026)

Enanta Pharmaceuticals (ENTA) Operating Income Growth (3y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.36%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 89.72%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 44.54%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -26.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -18.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 44.34%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 81.27%
10 Enanta Pharmaceuticals 383.29 Mn 193.78 Mn - 22.28%

Historic Data

Download Data
DateValue
Jun 30, 2026 22.28%
Mar 31, 2026 33.03%
Dec 31, 2025 27.89%
Sep 30, 2025 12.07%
Jun 30, 2025 16.58%
Mar 31, 2025 10.18%
Dec 31, 2024 8.18%
Sep 30, 2024 3.98%
Jun 30, 2024 10.60%
Mar 31, 2024 -3.33%
Dec 31, 2023 -41.56%
Sep 30, 2023 -16.19%
Jun 30, 2023 -17.12%
Mar 31, 2023 -49.21%
Dec 31, 2022 -63.01%
Sep 30, 2022 -83.77%
Jun 30, 2022 -120.12%
Mar 31, 2022 -196.08%
Dec 31, 2021 -45.68%
Sep 30, 2021 -43.89%